Dr Chun-Hung (Bruce) Chen, Founder & CEO
The emergence of additive manufacturing or 3D printing has triggered a groundbreaking transformation in mass production, boosting the overall speed, efficiency, and cost-effectiveness in manufacturing processes. However, its application in the medical field is jeopardized with quality and safety concerns, despite the adoption of innovative technologies or improved methodologies that supplement OEMs. “The lack of interoperability/ integration/coherence among material sciences, manufacturing machinery, and various medical regulations, along with the need for quality assurance creates significant barriers in the development of 3D printed medical devices and implants,” states Dr. Chun-Hung Chen (Bruce), founder and CEO of the Taiwan-based Advanced Biomedical Technology Inc. (ABT). Founded in 2017 by a team of material scientists and engineers, ABT is the brainchild of the collective industry experience of its founders that made an ambitious bid to break the barriers that hinder the successful adoption of 3D printing in the medical sector.
“ABT offers next-generation ‘3D printing total solutions’ for medical applications and superior, medical-grade filaments with distinct degradation time for R&D in tissue engineering and medical implants,” Bruce says.
The ‘total solutions’ from ABT hones an integrated package of 3D printing machinery and specialized materials, bolstered by the required quality assurance needed for medical devices. Its flagship product, MeDFila®
, constitutes a range of biodegradable filaments made up of polymers and polymer-ceramics composite that are exclusively designed for medical 3D printing applications.
ABT offers next-generation 3D printing total solutions for medical applications and superior medical-grade filaments for R&D in tissue engineering and medical implants
is available in two different grades—R&D grade, and Medical grade—to proactively meet the specific medical requirements through the early stages of prototyping, designing, or manufacturing of medical devices and implants. ABT’s extensive domain know-how equips clients with qualified OEM and ODM 3D printing services to manufacture medical implants and devices from their own designs or develop new products from scratch. Besides, the company delivers quality documentation of such operations to accelerate clinical approval process and ensure systemic quality control in the manufacturing of these devices.
The proprietary medical-grade printing system from ABT empowers manufacturers to improve the speed of delivery correlating to the development of implants at an affordable cost; the firm achieves this by maintaining consistent quality checks for products, materials, machinery, and processes. “Our highly modularized and flexible printing solutions are supplemented by a quality consultation service to ensure effective adoption of 3D printing across various medical specialties such as plastic surgery, orthopedics, cardiovascular, and more,” continues Bruce. Added to this, ABT’s dedicated team of experts assists clients in developing customized implants and devices for clinical usage, tissue engineering, or even drug release applications.
Unlike many of its competitors that provide either the material or the machinery, ABT offers a complete suite of medical-grade filaments, machinery, OEM and ODM services, and quality documentation to fulfill clients’ discrete requirements. By gathering every touch point in the product life cycle under one roof, the company provides a comprehensive platform that boosts manufacturing while regulating the quality and costs of production. Apart from high volume orders, ABT also undertakes ‘small quantity manufacturing’ for clients who require fewer products at unmatched quality and price, adding to the company’s value proposition in the market.
ABT’s experienced medical background and business acumen have bagged the testimonials of the Taiwanese and American markets for excellence in 3D printing of medical devices and implants. The company has recently completed its material certification and plans to advance toward the next round of funding in order to commemorate the final development of its GMP facility in the near future. ABT also looks forward to moving the company headquarters to the US within the next three years in an aim to tackle the evolving 3D printing challenges faced by a broader demographic of clients across America and Europe.